Drugs / APINOCALTAMIDE
APINOCALTAMIDE
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03165097 | Jul 2017 → Nov 2018 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT05301894 | Jun 2022 → Jan 2025 | developmental and epileptic encephalopathy, developmental and/or epileptic encephalopathy with spike-wave activation in sleep | Neurocrine Biosciences | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04625101 | Apr 2021 → Aug 2022 | developmental and epileptic encephalopathy, developmental and/or epileptic encephalopathy with spike-wave activation in sleep | Neurocrine Biosciences | Completed | Missed primary |
| Phase 2 | NCT04880616 | Apr 2021 → May 2022 | essential tremor | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03239691 | Oct 2017 → Apr 2018 | photosensitive epilepsy | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04123288 Comparator | Dec 2019 → Feb 2020 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APINOCALTAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4217292 ↗ |
| Known as | ACT-709478 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04123288 ↗ |
| Known as | Apinocaltamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4217292 ↗ |
| Known as | NBI-827104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05301894 ↗ |
| Action | Inhibit | “Triple T-type calcium channel blocker.” NCT04625101 ↗ |
| Modality | Small molecule | — CHEMBL4217292 ↗ |
| Route | Oral | “ascending multiple oral doses of ACT-709478 were administered” PMID 31994022 ↗ Mar 2020 |